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Abstract
Medullary thyroid carcinoma (MTC) metastasizes very early lymphogeneously. It has been shown that the presence
of lymph node metastases is associated with a worse outcome. Postoperative biochemical cure, i.e. normalization
of posttherapeutical calcitonin levels, has been shown to correlate with a better outcome. The rate of biochemical
cure decreases dramatically in the presence of lymph node metastases but can still be achieved in about 30-40%
of patients despite the presence of lymph node metastases.
In 2009, the American Thyroid Association (ATA) published guidelines on the management of MTC. Various
recommendations in the guidelines are dealing with the extent of lymph node dissection in different clinical
settings. This article summarizes and comments on these recommendations.
Background
Medullary thyroid carcinoma (MTC) metastasizes very
early lymphogenously.
The presence of initial lymph node metastases in non-
screening patients is generally reported to be higher than
50%, often as high as 75-80% [1,2]. Even bilateral lateral
lymph node involvement is quite frequent (>25%) [2] and
has been shown to be associated with distant metastases
[3]. In these advanced cases, biochemical cure, i.e. normal-
ization of posttherapeutical calcitonin levels, is extremely
rare [4].
It has been shown that the presence of lymph node
metastases in general is associated with a worse outcome
[5]. Interestingly, it has less clearly been shown that lym-
phadenectomy improves the outcome in patients with
MTC [5]. What has been shown is that, depending on
patient selection, biochemical cure can be achieved in
about 30-40% of patients with regional lymph node metas-
tases [4,6] which, however, is a significantly lower rate than
that for patients without lymph node metastases (90-100%)
[1,6]. Biochemical cure itself has been shown to correlate
with a better outcome [7-9] but late recurrence has been
shown.
That the extent of lymph node dissection is part of
ongoing discussion has apart from the unknown benefit
in a specific patient in part to do with the possible com-
plications that are accompanied with this procedure,
mainly hypoparathyroidism and nerve injury [10]. In
addition, in the presence of advanced disease, t.ex. distant
metastases, the benefit of lymph node dissection is even
more questionable.
ATA guidelines regarding lymphadenectomy
The guidelines published by the American Thyroid
Association (ATA) [11] contain various recommenda-
tions dealing with the extent of lymphadenectomy.
Clinically evident or highly suspected MTC
According to the guidelines, patients having MTC or
those where MTC is highly likely should undergo total
thyroidectomy and prophylactic central compartment
(level VI) neck dissection both with and without evi-
dence of cervical lymph node metastases in the absence
of advanced local invasion and distant metastases
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(recommendation 61 & 62). The lateral compartment
(level II-V) should be included in the case of ultra-
sound-confirmed lateral lymph node metastases (recom-
mendation 63). Preoperative ultrasound is therefore
indicated in all patients prior to surgery (recommenda-
tion 19).
Some members of the task force recommended pro-
phylactic inclusion of the lateral compartment recom-
mended in the presence of central compartment lymph
node metastases (recommendation 62). This recommen-
dation is based on the finding that the involvement of
the ipsilateral cervicolateral compartment correlates
with the number of lymph node metastases in the cen-
tral compartment [12].
Advanced disease
In general, a less aggressive approach is advised in the
presence of advanced local and/or distant metastases
while maintaining locoregional disease control to pre-
vent central neck morbidity (recommendation 64 & 65).
In patients with distant metastases, removal of small
asymptomatic and nonthreatening lymph node metas-
tases (<1 cm) is of unknown benefit and such lymph
nodes may be observed (recommendation 81).
Primary incomplete surgery
Following primary incomplete surgery, reoperation
including the central lymph node compartment is
recommended when neck US is suspicious for persistent
local disease in the central or lateral neck compartment
(recommendation 71) or when the basal serum calcito-
nin level is above the normal reference range (recom-
mendation 72).
If not previously performed, node dissection in both
the central and lateral compartment should be compart-
ment-oriented. Removal of only grossly metastatic
lymph nodes, or other limited procedures, should be
avoided in these instances (recommendation 77). This
recommendation is based on the fact that removal of
only grossly metastatic lymph nodes correlates with a
lower calcitonin normalization rate, a higher reoperation
rate and a lower survival rate [13].
In view of the ATA guidelines, central lymph node dis-
section remains controversial if primary surgery only con-
sisted of total thyroidectomy in patients with continuously
elevated calcitonin levels in the absence of radiographic
findings (recommendation 78). It is explained in the guide-
lines that controversy also exist due to the increased risk of
harm. It is obvious that the surgical experience and exper-
tise plays an important role in this regard. Of note, it must
be primarily assumed that continuously elevated calcitonin
levels following thyroidectomy mainly are due to lymph
node metastases left in situ. Calcitonin normalization has
in selected patients been observed in up to 35-40% even
after reoperation [14,15] and may actually be as low as 6%
if one waits for radiographic positive findings [16]. Thus
the recommendation to wait for positive imaging as sug-
gested by the ATA guidelines is questionable.
Hereditary MTC
In patients with hereditary MTC, early identification of
patients, e.g. through family screening, may enable to
limit the extent of surgery to the thyroid gland since
lymph node metastases may be very unlikely if preo-
perative calcitonin levels are normal [17,18]. Besides
patient’s age, primary tumor size and calcitonin levels
may be helpful in determining the surgical extent. The
ATA guidelines give some recommendations in this
regard (recommendations 33, 35, 40-43). Since this
review is focusing on clinically evident MTC, these
recommendations will not be discussed in detail here.
Further comments
In general, lymph node dissection should be very restric-
tive in the presence of advanced local and/or distant dis-
ease. This is justified by the very low chance to cure
those patients [6] where no benefit might be gained
from the lymph node dissection. In these instances, the
calcitonin doubling-times may be of help assessing
patient’s prognosis where doubling-tomes less than 6
months are very unfavourable [19].
Clinically evident or highly suspected lymph node
metastases
Taken the above into account, dissection is almost always
indicated in the presence of cervical lymph nodes metas-
tases. Clinically, the presence of lymph node metastases
is most often assumed in the presence of enlarged lymph
nodes. Fine-needle aspiration is rarely performed. How-
ever, lymph node metastases in MTC are typically rather
small in size and, thus, normal lymph node size does not
exclude the presence of metastases.
Unknown lymph node status
If no enlarged lymph nodes are present, the extent of
lymph node dissection is much more difficult to assess.
This situation, however, is very common.
Most surgeons would recommend central lymphade-
nectomy (defined as dissection of level VI) in all patients
with sporadic MTC and in all screening patients with ele-
vated calcitonin levels at the time thyroidectomy is per-
formed due to the high likelhood of the presence of
positive lymph nodes [20]. The exception are screening
patients with normal calcitonin levels that probably have
an extremely low risk that lymph node metastases exist
[17,18]. These patients may therefore forego lymphade-
nectomy. As mentioned before, one reason to avoid cer-
vical lymphadenectomy is the observed higher rate of
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complications [10]. The reason to perform central lym-
phadenectomy synchronous with thyroidectomy is that
metachronous lymphadenectomy confers an even higher
risk of complications. This does not apply to the lateral
compartments (level II-V) that are not touched if the pre-
vious operation consist of thyroidectomy both with and
without central lymphadenectomy.
Since the ipsilateral cervicolateral compartment contains
almost as often lymph node metastases as the central
compartment [21], some surgeons would recommend per-
forming both central and lateral lymphadenactomy syn-
chronous with thyroidectomy. Others have recommended
lateral lymph node dissection “on demand”, i.e. in the
setting of measurable postoperative bCT and/or sCT levels
indicating LN metastasis [22]. In the case of contralateral
positive lymph nodes, the chance of biochemical cure
decreases dramatically [21] and no beneficial outcome has
been shown if lymphadenectomy is performed in these
patients.
Assessing the lymph node status
The question is how the extent of lymph node metastases
can be assessed pre- or at the latest intraoperatively in
MTC patients.
Imaging techniques
The accuracy of computed tomography and ultrasonogra-
phy for evaluating cervical lymph node metastases in
patients with papillary thyroid carcinoma is not very high,
74% vs. 68 resp. [23]. Since it is known that lymph mode
metastases in MTC are often rather small as compared to
papillary thyroid carcinoma, the accuracy is expected to be
lower which has indeed been shown [24]. Both, somatosta-
tin receptor scintigraphy and, in particular, FDG-PET have
been used with some success in detecting lymph node
metastaes preoperatively but the reported series are small
[24-28].
In reoperative cases, a variety of imaging techniques
(ultrasound, computed tomography, FDG-PET) seems to
have a low sensitivity (56%, 42%, and 32%, respectively).
Thus, currently available imaging techniques are of
minor value identifying small lymph node metastases.
Ultrasound, which is readily available, is the investigation
of choice and should always be performed first.
Venous sampling
In reoperative cases, it has been shown that pentagastrin-
stimulated intravenous calcitonin sampling followed by
targeted surgery may be beneficial in the diagnostic
work-up of MTC after thyroidectomy [29]. However, the
number of reported cases is low and the real value is not
known yet.
Primary tumor size
Even small tumors (<1 cm) inherit a risk for lymph node
metastases that increases with tumor size [30]. Patients
having a primary tumor of less than 5 mm in size have a
risk of having lymph node metastases between 13-20% if
sporadic and between 6-14% if hereditary. The biochem-
ical cure rates at these early stages are 69-85% and 80-
96%, respectively. Concerning tumors smaller than 1 cm
in size, lymph node metastases are found in 5-31% and the
biochemical cure ranges from 71% to 100% (reviewed in
[30]). Thus, even at these early stages, lymph node metas-
tases are not uncommon [31].
Thus, lymph node metastases are not uncommon even
in small primary tumors. The tumor size is, hence, of
less value in assessing the presence of lymph node
metastases in patients with MTC.
Lymph node metastases in the central compartment
Studies have shown that the involvement of the ipsilat-
eral cervicolateral compartment correlates with the
number of lymph node metastases in the central com-
partment. If more than 3 lymph nodes in the cervico-
central compartment were involved, almost all patients
had lateral lymph node metastases in one study [12].
This “marker”, however, is of less use in the clinical set-
ting in the absence of macroscopically enlarged lymph
nodes since it is not possible to determine the numbers
of central lymph node metastases within a decent time
period intraoperatively so far. Of note, lateral lymph
node metastases were found in about 10% even in the
absence of central lymph node metastases. This finding,
i.e. the presence of cervicolateral lymph node metastases
without cervicocentral compartment involvement, often
referred to as skip metastases [32], has even been found
in up to 35% by others [33].
Calcitonin levels
Concerning microMTC (<1 cm), calcitonin levels cannot
distinguish between patients with and without lymph
node metastases [22]. This is also true for patients with
larger primary tumors even though higher basal calcito-
nin levels correlate better than pentagastrin stimulated
calcitonin levels with lymph node involvement [20]. In
the latter study, both central and ipsilateral lateral lymph
node metastases were present in about 10% of the
patients already at a basal level of 20 pg/mL. In patients
higher than 200 pg/mL, contralateral lateral lymph node
involvement was observed in at least 12% of the patients.
One study showed that intraoperative stimulated calcito-
nin levels following thyroidectomy and central lymph node
dissection correlated well with the presence of lateral
lymph node metastases [34]. The intraoperative usefulness
of this technique would require quick calcitonin assays.
Currently, the analysis takes several hours.
Age
While age plays an important role assessing timing and
extent in patients with hereditary MTC [35], it does not
seem to play a role in sporadic MTC.
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Other “markers”
Beside these more traditional markers, other markers
are sought after.
Of interest, one such “marker” has been cervical pain. In
one study, the authors reported that roughly 80% of their
patients with MTC presented with neck pain (defined as
any subjective complaint of anterior neck discomfort,
ache, pressure, or sharp, throbbing, or dull sensations in
the region of the thyroid gland, with or without palpation)
as opposed to only 6% of their patients with papillary thyr-
oid carcinoma [36]. However, even 36% of those without
pain had lymph node metastases.
Desmoplastic stromal reaction is one of those intrao-
perative markers that appear to have more clinical value.
In one study analyzing 120 MTCs, it was shown that des-
moplastic stromal reaction, which can be assessed intrao-
peratively, has a low (38%) sensitivity of predicting N0 but
a very high (100%) specificity. The authors therefore
recommend avoiding lymph node dissection in the
absence of desmoplastic stromal reaction [37]. The results
where later shown to be reproducible by other pathologists
[38] but larger prospective studies are missing yet.
Conclusions
If advanced disease is absent, central lymph node dissec-
tion is almost always indicated at the initial operation in
patients with clinically evident MTC. Synchronous inclu-
sion of the ipsilateral lateral compartment is recom-
mended by some but might probably also be done ”on
demand” if postoperative calcitonin levels remain elevated.
In reoperative cases, the extent of lymph node dissec-
tion depends primarily on the extent of previous opera-
tion(s). Compartments that have not been operated on in
a systematic way, i.e. dissection of all lymph node and the
connective tissue “en bloc”, should be operated in this
manner. Node picking should be reserved to those com-
partments that have been operated on systematically.
I these cases, positive imaging is required. This approach,
however, has not been proven to be of any benefit for the
patient.
Future research has to concentrate on improving pre-
operative imaging and on the identification of intrao-
perative measurable markers that correlate with the
presence or absence of lymph node metastases with a
high accuracy.
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